These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33989889)

  • 41. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
    Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
    J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
    Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
    Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas.
    Johncilla M; Chen Z; Sweeney J; Yantiss RK
    Am J Surg Pathol; 2018 Dec; 42(12):1686-1692. PubMed ID: 30179899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intertumoral Heterogeneity of CD3
    Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients.
    Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
    Oncol Res Treat; 2017; 40(11):702-706. PubMed ID: 29065415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Impact of Mismatch Repair Protein Testing on Outcome of Early Staged Colorectal Carcinomas.
    Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
    J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
    Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
    Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.
    Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C
    Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
    Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
    Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study.
    Wang Z; Tang X; Wu X; Yang M; Wang D
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31804673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer.
    He WZ; Hu WM; Wang F; Rong YM; Yang L; Xie QK; Yang YZ; Jiang C; Qiu HJ; Lu JB; Zhang B; Ding PR; Xia XJ; Shao JY; Xia LP
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1174-1183. PubMed ID: 31590148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
    Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
    Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
    Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers.
    Park JW; Chang HJ; Park S; Kim BC; Kim DY; Baek JY; Kim SY; Oh JH; Choi HS; Park SC; Jeong SY
    Ann Surg Oncol; 2010 Nov; 17(11):2839-46. PubMed ID: 20549564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
    Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
    Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer.
    Kim HR; Kim HC; Yun HR; Kim SH; Park CK; Cho YB; Yun SH; Lee WY; Chun HK
    Ann Surg Oncol; 2013 Nov; 20(12):4031-40. PubMed ID: 22732839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.